Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings

The Lancet Infectious Diseases

Volumn 8, Issue 8, 2008, Pages 516-523

  Meintjes, Graeme ^a   Lawn, Stephen D ^b,c   Scano, Fabio ^d   Maartens, Gary ^a   French, Martyn A ^e   Worodria, William ^f   Elliott, Julian H ^g   Murdoch, David ^h   Wilkinson, Robert J ^a,i,j   Seyler, Catherine ^k   John, Laurence ^l   van der Loeff, Maarten Schim ^m   Reiss, Peter ^m   Lynen, Lut ⁿ   Janoff, Edward N ^o   Gilks, Charles ^p   Colebunders, Robert ^n,q  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Institute of Infectious Disease and Molecular Medicine   (South Africa)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d THD   (Switzerland)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f MAKERERE UNIVERSITY   (Uganda)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^j WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^k UNIVERSITÉ DE BORDEAUX   (France)

^l CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^m ACADEMIC MEDICAL CENTER   (Netherlands)

ⁿ INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^o UNIVERSITY OF COLORADO   (United States)

^p WORLD HEALTH ORGANIZATION   (Switzerland)

^q UNIVERSITY OF ANTWERP   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CORTICOSTEROID; EFAVIRENZ; ISONIAZID; LAMIVUDINE; RIFAMPICIN; STAVUDINE;

ARTICLE; CONSENSUS DEVELOPMENT; DISEASE ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INTERNATIONAL COOPERATION; PRIORITY JOURNAL; TUBERCULOSIS;

EID: 47549086736     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(08)70184-1     Document Type: Note

References (44)

1. Shelburne S., and Hamill R. The immune reconstitution inflammatory syndrome. AIDS Rev 5 (2003) 67-79
2. French M., Price P., and Stone S. Immune restoration disease after antiretroviral therapy. AIDS 18 (2004) 1615-1627
3. Lawn S., Bekker L., and Miller R. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 5 (2005) 361-373
4. Katabira E., and Oelrichs R. Scaling up antiretroviral treatment in resource-limited settings: successes and challenges. AIDS 21 suppl 4 (2007) S5-10
5. Corbett E., Watt C., Walker N., et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 163 (2003) 1009-1021
6. Lawn S., Myer L., Bekker L., and Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 20 (2006) 1605-1612
7. Colebunders R., John L., Huyst V., Kambugu A., Scano F., and Lynen L. Tuberculosis immune reconstitution inflammatory syndrome in countries with limited resources. Int J Tuberc Lung Dis 10 (2006) 946-953
8. Kumarasamy N., Chaguturu S., Mayer K., et al. Incidence of immune reconstitution syndrome in HIV/tuberculosis-coinfected patients after initiation of generic antiretroviral therapy in India. J Acquir Immune Defic Syndr 37 (2004) 1574-1576
9. Manosuthi W., Kiertiburanakul S., Phoorisri T., and Sungkanuparph S. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J Infect 53 (2006) 357-363
10. Lawn S., Myer L., Bekker L., and Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 21 (2007) 335-341
11. WHO. TB/HIV research priorities in resource-limited settings. Report of an expert consultation (February 14-15, 2005), World Health Organization, Geneva, Switzerland
12. Robertson J., Meier M., Wall J., Ying J., and Fichtenbaum C. Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis 42 (2006) 1639-1646
13. Shelburne S., Montes M., and Hamill R. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother 57 (2006) 167-170
14. Shelburne S., Hamill R., Rodriguez-Barradas M., et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 81 (2002) 213-227
15. Coetzee D., Hildebrand K., Boulle A., et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 18 (2004) 887-895
16. Kilaru K., Kumar A., Sippy N., Carter A., and Roach T. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country. HIV Med 7 (2006) 99-104
17. Orrell C., Harling G., Lawn S., et al. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther 12 (2007) 83-88
18. Phillips P., Bonner S., Gataric N., et al. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up. Clin Infect Dis 41 (2005) 1483-1497
19. Van den Bergh R., Vanham G., Raes G., De Baetselier P., and Colebunders R. Mycobacterium-associated immune reconstitution disease: macrophages running wild?. Lancet Infect Dis 6 (2006) 2-3
20. Dhasmana D., Dheda K., Ravn P., Wilkinson R., and Meintjes G. Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy: pathogenesis, clinical manifestations and management. Drugs 68 (2008) 191-208
21. Shelburne S., Visnegarwala F., Darcourt J., et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 19 (2005) 399-406
22. Narita M., Ashkin D., Hollender E., and Pitchenik A. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 158 (1998) 157-161
23. Breen R., Smith C., Bettinson H., et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax 59 (2004) 704-707
24. Breton G., Duval X., Estellat C., et al. Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy. Clin Infect Dis 39 (2004) 1709-1712
25. Michailidis C., Pozniak A., Mandalia S., Basnayake S., Nelson M., and Gazzard B. Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis. Antivir Ther 10 (2005) 417-422
26. Burman W., Weis S., Vernon A., et al. Frequency, severity and duration of immune reconstitution events in HIV-related tuberculosis. Int J Tuberc Lung Dis 11 (2007) 1282-1289
27. McIlleron H., Meintjes G., Burman W., and Maartens G. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis 196 suppl 1 (2007) S63-S75
28. Olalla J., Pulido F., Rubio R., et al. Paradoxical responses in a cohort of HIV-1-infected patients with mycobacterial disease. Int J Tuberc Lung Dis 6 (2002) 71-75
29. Bourgarit A., Carcelain G., Martinez V., et al. Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS 20 (2006) F1-F7
30. Hawkey C., Yap T., Pereira J., et al. Characterization and management of paradoxical upgrading reactions in HIV-uninfected patients with lymph node tuberculosis. Clin Infect Dis 40 (2005) 1368-1371
31. Cheng V., Yam W., Woo P., et al. Risk factors for development of paradoxical response during antituberculosis therapy in HIV-negative patients. Eur J Clin Microbiol Infect Dis 22 (2003) 597-602
32. Reiser M., Fatkenheuer G., and Diehl V. Paradoxical expansion of intracranial tuberculomas during chemotherapy. J Infect 35 (1997) 88-90
33. Bonnet M., Pinoges L., Varaine F., et al. Tuberculosis after HAART initiation in HIV-positive patients from five countries with a high tuberculosis burden. AIDS 20 (2006) 1275-1279
34. Lawn S., Badri M., and Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 19 (2005) 2109-2116
35. Seyler C., Toure S., Messou E., Bonard D., Gabillard D., and Anglaret X. Risk factors for active tuberculosis after antiretroviral treatment initiation in Abidjan. Am J Respir Crit Care Med 172 (2005) 123-127
36. Moore D., Liechty C., Ekwaru P., et al. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS 21 (2007) 713-719
37. Lawn S., Wilkinson R., Lipman M., and Wood R. Immune reconstitution and "unmasking" of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med 177 (2008) 680-685
38. Moore D., Hogg R., Yip B., et al. Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J Acquir Immune Defic Syndr 40 (2005) 288-293
39. Kaplan S., Ferrari G., Wrin T., et al. Longitudinal assessment of immune response and viral characteristics in HIV-infected patients with prolonged CD4(+)/viral load discordance. AIDS Res Hum Retroviruses 21 (2005) 13-16
40. Breen R., Smith C., Cropley I., Johnson M., and Lipman M. Does immune reconstitution syndrome promote active tuberculosis in patients receiving highly active antiretroviral therapy?. AIDS 19 (2005) 1201-1206
41. Goldsack N., Allen S., and Lipman M. Adult respiratory distress syndrome as a severe immune reconstitution disease following the commencement of highly active antiretroviral therapy. Sex Transm Infect 79 (2003) 337-338
42. John L., Baalwa J., Kalimugogo P., et al. Response to "does immune reconstitution promote active tuberculosis in patients receiving highly active antiretroviral therapy?". AIDS 19 (2005) 2049-2050
43. Dautremer J., Pacanowski J., Girard P., Lalande V., Sivignon F., and Meynard J. A new presentation of immune reconstitution inflammatory syndrome followed by a severe paradoxical reaction in an HIV-1-infected patient with tuberculous meningitis. AIDS 21 (2007) 381-382
44. WHO. Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents: recommendations for HIV-prevalent and resource-constrained settings (2006), Stop TB Department, Department of HIV/AIDS, World Health Organization, Geneva